$EIKN News
Last published 1d ago
- 1d agoEIKNEikon Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoEIKNEikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswireMILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported third quarter 2026 financial results and provided updates on its programs.
- 1w agoEIKNEikon Therapeutics to Participate in Multiple Investor Conferences in NovemberGlobeNewswireCEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call seriesCMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley
- 2w agoEIKNEikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology CongressGlobeNewswireTLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile
- 3w agoEIKNEikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology CongressGlobeNewswireInitial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies
- 3w agoEIKNEikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressGlobeNewswirePresentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and
- 4w agoEIKNEikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate CancerGlobeNewswireMILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address
- 2mo agoEIKNEikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific OfficerGlobeNewswireMILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address
- 2mo agoEIKNEikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor FitzgeraldGlobeNewswireMILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address
- 3mo agoEIKNEikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswireEikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001
- 3mo agoEIKNEikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced MelanomaGlobeNewswireSelected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following
- 3mo agoEIKNEikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory BoardGlobeNewswireMILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address
- 3mo agoEIKNEikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung CancerGlobeNewswireMILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet
- 3mo agoEIKNEikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) CongressGlobeNewswirePresentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4
- 5mo agoEIKNEikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of DirectorsGlobeNewswireMILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious
- 5mo agoEIKNEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical OncologyGlobeNewswireTeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening
- 5mo agoEIKNEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical OncologyGlobeNewswirePresentations to cover progress across Eikon's most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"),
- 6mo agoEIKNEikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswireMaintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus on three priority
- 7mo agoEIKNEikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate UpdatesGlobeNewswireClosed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung
- 9mo agoEIKNEikon Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireMILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet